# Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

> **NCT00691652** · PHASE1,PHASE2 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 2 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** clofarabine
- **GENETIC:** DNA methylation analysis
- **GENETIC:** gene expression analysis
- **GENETIC:** microarray analysis
- **GENETIC:** polymerase chain reaction
- **OTHER:** high performance liquid chromatography
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00691652
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2009-01
- **Final completion:** 2009-04
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Funding ended when only one subject enrolled and subject withdrew early.
- **Last updated:** 2019-11-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00691652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00691652, "Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00691652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*